Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.

被引：0

作者：

Avallone, Antonio

Giuliani, Francesco

Nasti, Guglielmo

Montesarchio, Vincenzo

Santabarbara, Giuseppe

Leo, Silvana

De Stefano, Alfonso

Rosati, Gerardo

Lolli, Ivan

Tamburini, Emiliano

Colombo, Alfredo

Santini, Daniele

Silvestro, Lucrezia

Facchini, Gaetano

Mannavola, Francesco

Febbraro, Antonio

Troncone, Giancarlo

Sobrero, Alberto F.

Giannarelli, Diana

Budillon, Alfredo

机构：

[1] Ist Nazl Tumori Fdn G Pascale, Naples, Italy

[2] NCI Giovanni Paolo II, Bari, Italy

[3] Ist Nazl Tumori Fdn G Pascale, Naples, Italy

[4] AORN Coll Osped Monaldi Cotugno CTO, Naples, Italy

[5] Azienda Osped Rilievo Nazl SG Moscati, Oncol Med, Avellino, Italy

[6] Osped Vito Fazzi, Lecce, Italy

[7] San Carlo Hosp, Med Oncol Unit, Potenza, Italy

[8] IRCCS Saverio Bellis Hosp, Bari, Italy

[9] Tricase City Hosp, Dept Oncol, Tricase, Italy

[10] Casa Cura Macchiarella, UO Oncol Med, Palermo, Italy

[11] Fdn Policlin Campus Bio Med, Dept Med Oncol, Rome, Italy

[12] ASLNapoli 2 Nord Osped Grazie Pozzuoli, Pozzuoli, Italy

[13] Univ Bari, Bari, Italy

[14] Osped Sacro Cuore Gesu Fatebenefratelli, Oncol Med, Benevento, Italy

[15] Univ Federico II, Dept Publ Hlth, Naples, Italy

[16] IRCCS Osped Policlin San Martino, Genoa, Italy

[17] Fdn Policlin Univ A Gemelli, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3503

引用

页数：1